Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 ROE % is 3.59% as of Jun. 2026, which is 14% below its 10-year median of 4.19. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 799 Medical Devices & Instruments companies, ICU Medical ranks worse than 52.94% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ICU Medical's annualized net income for the quarter that ended in Jun. 2026 was €66 Mil. ICU Medical's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was €1,847 Mil. Therefore, ICU Medical's annualized ROE % for the quarter that ended in Jun. 2026 was 3.59%.
The historical rank and industry rank for ICU Medical's ROE % or its related term are showing as below:
STU:IC7'
s ROE % Range Over the Past 10 Years
Min: -5.76 Med: 4.19 Max: 10.17
Current: 1.42
During the past 13 years, ICU Medical's highest ROE % was 10.17%. The lowest was -5.76%. And the median was 4.19%.
STU:IC7's ROE % is ranked worse than 52.94% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.68
vs STU:IC7: 1.42
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ICU Medical ROE % Related Terms
ICU Medical ROE % Historical Data
* Premium members only.
The historical data trend for ICU Medical's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ICU Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's ROE % distribution charts can be found below:
* The bar in red indicates where ICU Medical's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
ICU Medical (STU:IC7) has a ROE % of 3.59% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ICU Medical and its competitors. This is 14% below median its historical median of 4.19. According to the industry distribution chart, ICU Medical ranks #423 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 52.9%.
Is ICU Medical's ROE % too high?
ICU Medical's current ROE % of 3.59% is 14% below median its 10-year median of 4.19. The Medical Devices & Instruments industry median ROE % is 2.68. ICU Medical's value of 3.59% is 34% above this industry median. Based on the distribution chart, ICU Medical ranks #423 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's ROE % compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #423 out of 799 companies for ROE %. This places ICU Medical in the lower half of its industry. The industry median ROE % is 2.68. ICU Medical's value of 3.59% is 34% above this benchmark. While the company's 10-year median is 4.19 vs. the industry median of 2.68, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.68, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current ROE % of 3.59% is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current ROE % is 3.59%, which is 14% below median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current ROE % is 3.59%, which is 14% below median its 10-year median of 4.19 and 34% above the Medical Devices & Instruments industry median of 2.68. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current ROE % is 3.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
ROE %: 3.59% (14% below median its 10-year median of 4.19)
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
Industry Position: 34% above the Medical Devices & Instruments median (#423 of 799)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
